For Most Patients, Maximize Oral Lipid Therapy and Skip PCSK9s For Most Patients, Maximize Oral Lipid Therapy and Skip PCSK9s

A simulation study shows that for 86% of patients who require cholesterol lowering, statins and ezetimibe are sufficient, while the remaining 14% will need add-on PCSK9 inhibitors to reach target LDL levels.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news